Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients.
Preuner
J G
JG
Clinic for Cardio-Thoracic Surgery, University of Regensburg, Germany. Preuner@rkhtcnw1.ngate.uniregensburg.de
Lehle
K
K
Keyser
A
A
Merk
J
J
Rupprecht
L
L
Goebels
R
R
D000638:Amiodarone / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D001663:Bilirubin / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D006207:Half-Life; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009504:Neutrophils / Q000378:metabolism
D000889:Anti-Arrhythmia Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; C036116:desethylamiodarone; D000638:Amiodarone; D001663:Bilirubin